



## Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates

November 10, 2021

Click [here](#) to register for webcast

Company plans to file Q3 2021 10-Q on November 15, 2021

SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, November 15, 2021 at 8:30 a.m. Eastern Time to review third-quarter 2021 financials and provide business updates.

### Participation Instructions for Webcast

When: Monday, November 15, 2021 at 8:30 AM Eastern Time

Participant Registration & Access Link: [Click Here](#)

### About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi<sup>®</sup> (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Crofelemer is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Napo EU S.p.A., the majority owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe.

For more information about Jaguar, please visit <https://jaguar.health>. For more information about Napo Pharmaceuticals, visit [www.napopharma.com](http://www.napopharma.com). For more information about Napo EU, visit [www.napoeu.com](http://www.napoeu.com).

### About Mytesi<sup>®</sup>

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at [Mytesi.com](http://Mytesi.com). Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal *Croton lechleri* tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

### Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's expectation that an investor webcast will take place November 15, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

### CONTACT:

Peter Hodge

Jaguar Health, Inc.

[phodge@jaguar.health](mailto:phodge@jaguar.health)

Jaguar-JAGX

**SOURCE:** Jaguar Health, Inc.

[accesswire.com](https://www.accesswire.com)

<https://www.accesswire.com/671996/Jaguar-Health-to-Host-Investor-Webcast-Monday-November-15th-at-830-AM-Eastern-Time-Regarding-Q3-2021-Financials-Business-Updates>